Alpha 1 Biomedicals
Executive Summary
Vincent Simmon, PhD, named president and CEO of the Washington, D.C.-based peptide R&D firm. He joins the company from W. R. Grace, where he served as VP-biotechnology research. Earlier, Simmon held a number of executive positions with Genex Corp., including VP-R&D. Two of Simmon's immediate priorities at Alpha 1 Biomedicals will be the commercialization of Thymosin Alpha 1 and an AIDS vaccine product, HGP-30, based on the p17 core antigen. The latter, which is about to begin human testing in the state of California, is being developed via a joint venture with Cel-Sci.